{
    "2021-03-19": [
        [
            {
                "time": "",
                "original_text": "睿智董事被采取强制措施丨睿智孙公司二审结果丨同仁堂董事辞职丨恒瑞突破疗法丨恒瑞、复星、贝达、恩华临床 董监高成员异常事件",
                "features": {
                    "keywords": [
                        "睿智董事",
                        "强制措施",
                        "同仁堂董事辞职",
                        "恒瑞突破疗法",
                        "复星",
                        "贝达",
                        "恩华",
                        "董监高异常事件"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业：业绩弹性逐步释放 关注一季报高增长品种",
                "features": {
                    "keywords": [
                        "医药生物行业",
                        "业绩弹性",
                        "一季报高增长"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}